Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on November 21st, 2023%
A challenge competition with a $50 million purse seeks new strategies to attack the global substance abuse epidemic, including personalized diagnostics and treatments. . . . → Read More: Challenge Seeks Precise Addiction Strategies, Biomarkers, Treatments
By Alan, on November 20th, 2023%
Data from three health repositories show a simple blood test reveals inherited and acquired genetic indicators, analyzed with artificial intelligence, to detect coronary heart disease. . . . → Read More: A.I. Analytics Show Blood Test Detects Heart Disease
By Alan, on November 17th, 2023%
Health authorities in Sweden authorized the start of a clinical trial testing insulin-producing cells from donors engineered to prevent immune reactions in people with type 1 diabetes. . . . → Read More: Trial Okayed to Transplant Donated Islet Cells for Type 1 Diabetes
By Alan, on November 16th, 2023%
Generate:Biomedicines describes its Chroma generative A.I. model in yesterday’s issue of the journal Nature, and is making the model available as open source through GitHub. . . . → Read More: Generative A.I. Designs Novel Synthetic Proteins
By Alan, on November 15th, 2023%
A clinical trial in a small group of participants suggests a cannabinoid drug is safe and well-tolerated, and reduces agitation among patients with Alzheimer’s disease. . . . → Read More: Cannabinoid Shown Safe, Lowers Agitation in Alzheimer’s Patients
By Alan, on November 14th, 2023%
A company formed earlier this year is developing precision treatments for bacteria resistant to conventional antibiotics, and raising £4.3 million ($US 5.4 million) in seed funds. . . . → Read More: Start-Up Developing Precision Antibiotics for Resistant Bacteria
By Alan, on November 13th, 2023%
A developer of synthetic antibodies for neurodegenerative disorders delivered like gene therapies is raising €129 million ($US 138 million) in its first venture funding round. . . . → Read More: Antibody/Gene Therapy Biotech Gains $138 Million in Early Funds
By Alan, on November 11th, 2023%
Venture funding for digital health start-ups continued heading down in the third quarter of 2023, reaching low levels not seen in almost a decade. . . . → Read More: Infographic – Digital Health Funding Continues Slide
By Alan, on November 10th, 2023%
Results of a clinical trial show a peanut allergy treatment formulated as a toothpaste can safely deliver immunotherapy to raise recipients’ peanut tolerance. . . . → Read More: Peanut Allergy Toothpaste Shown Safe in Trial
By Alan, on November 9th, 2023%
A new challenge competition with $1 million in prizes seeks novel techniques for conducting biomedical research with data on human physiology and artificial intelligence. . . . → Read More: Challenge Seeks Transformative Human/A.I. Research Tech
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|